Shares of Crispr Therapeutics AG (NASDAQ:CRSP) saw an uptick in trading volume on Monday . 1,370,533 shares changed hands during trading, an increase of 126% from the previous session’s volume of 605,627 shares.The stock last traded at $44.85 and had previously closed at $39.85.
A number of research firms have recently issued reports on CRSP. Roth Capital increased their price target on Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th. Jefferies Financial Group began coverage on Crispr Therapeutics in a research report on Thursday, August 1st. They set a “buy” rating and a $64.00 price target on the stock. Canaccord Genuity began coverage on Crispr Therapeutics in a research report on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Piper Jaffray Companies reissued an “overweight” rating on shares of Crispr Therapeutics in a research report on Monday, October 21st. Finally, William Blair reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 30th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $57.25.
The business has a 50-day moving average of $42.04 and a two-hundred day moving average of $43.44. The company has a market cap of $2.17 billion, a P/E ratio of -13.04 and a beta of 3.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 13.96 and a quick ratio of 13.96.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, July 29th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.84). Crispr Therapeutics had a negative net margin of 15,136.56% and a negative return on equity of 51.49%. The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $47.57 million. During the same period in the previous year, the business earned ($0.82) EPS. Crispr Therapeutics’s revenue for the quarter was down 70.8% compared to the same quarter last year. Equities analysts anticipate that Crispr Therapeutics AG will post -3.85 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the stock. NEXT Financial Group Inc boosted its holdings in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares in the last quarter. Benjamin Edwards Inc. boosted its holdings in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares in the last quarter. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics in the third quarter worth about $26,000. US Bancorp DE boosted its holdings in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares in the last quarter. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics in the second quarter worth about $39,000. 50.23% of the stock is currently owned by institutional investors.
Crispr Therapeutics Company Profile (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How to calculate the intrinsic value of a stock
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.